Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study

Exclusion Criteria

• •Neoadjuvant therapy performed before operation;
• •Blood transfusion performed during operation or within 2 weeks before operation;
• •Incomplete baseline samples, including preoperative plasma samples, surgical tumor tissue samples and plasma samples 3-7 days after operation;
• •Two consecutive test points missing or three plasma samples missing in total before a positive ctDNA time point
• •Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;
• •Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;
• •Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;
• •Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;
• •Significant impairment of important organ function;
• •Other conditions in which the investigator believes that the patient should not participate in this trial.